Johnson Joseph

Johnson Joseph

Auto-generated profile, based on publicly available information

Johnson Joseph

Oxford University Hospitals Trust, Oxford, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2018 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
NLNina Linder
Nina Linder
JTJenny C Taylor
Jenny C Taylor
RCRichard Colling
Richard Colling
RPRobert Pell
Robert Pell
EAEdward Alveyn
Edward Alveyn
CVClare Verrill
Clare Verrill
Aims: To evaluate if a deep learning algorithm can be trained to identify tumour-infiltrating lymphocytes (TILs) in tissue samples of testicular germ cell tumours and to assess whether the TIL counts correlate with relapse status of the patient. Methods: TILs were manually annotated in 259 tumour regions from 28 whole-slide images (WSIs) of H&E-stained tissue samples. A deep learning algorithm was trained on half of the regions and tested on the other half. The algorithm was further applied to larger areas of tumour WSIs from 89 patients and correlated with clinicopathological data. Results: A correlation coefficient of 0.89 was achieved when comparing the algorithm with the manual TIL count in the test set of images in which TILs were present (n=47). In the WSI regions from the 89 patient samples, the median TIL density was 1009/mm 2 . In seminomas, none of the relapsed patients belonged to the highest TIL density tertile (>2011/mm 2 ). TIL quantifications performed visually by three pathologists on the same tumours were not significantly associated with outcome. The average interobserver agreement between the pathologists when assigning a patient into TIL tertiles was 0.32 (Kappa test) compared with 0.35 between the algorithm and the experts, respectively. A higher TIL density was associated with a lower clinical tumour stage, seminoma histology and lack of lymphovascular invasion. Conclusions: Deep learning–based image analysis can be used for detecting TILs in testicular germ cell cancer more objectively and it has potential for use as a prognostic marker for disease relapse.

12 November 2017 in BJU International
Verified
Journal Article
Closed access
PDF file
GSGlenda Scandura
Glenda Scandura
CVClare Verrill
Clare Verrill
APAndrew Protheroe
Andrew Protheroe
JJJohnson Joseph
Johnson Joseph
WAWendy Ansell
Wendy Ansell
DBDaniel M. Berney
Daniel M. Berney

25 October 2018 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
RWRobert A. Watson
Robert A. Watson
HPHugo De La Peña
Hugo De La Peña
MTMaria T. Tsakok
Maria T. Tsakok
JJJohnson Joseph
Johnson Joseph
SSSara Stoneham
Sara Stoneham
APAndrew Protheroe
Andrew Protheroe
Bleomycin, a cytotoxic chemotherapy agent, forms a key component of curative regimens for lymphoma and germ cell tumours. It can be associated with severe toxicity, long-term complications and even death in extreme cases. There is a lack of evidence or consensus on how to prevent and monitor bleomycin toxicity. We surveyed 63 germ cell cancer physicians from 32 cancer centres across the UK to understand their approach to using bleomycin. Subsequent guideline development was based upon current practice, best available published evidence and expert consensus. We observed heterogeneity in practice in the following areas: monitoring; route of administration; contraindications to use; baseline and follow-up investigations performed, and advice given to patients. A best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours has been developed and includes recommendations regarding baseline investigations, the use of pulmonary function tests, route of administration, monitoring and patient advice. It is likely that existing heterogeneity in clinical practice of bleomycin prescribing has significant economic, safety and patient experience implications. The development of an evidence-based consensus guideline was supported by 93% of survey participants and aims to address these issues and homogenise practice across the UK.

1 April 2019 in Cancer Epidemiology
Verified
Journal Article
Closed access
BNBrian David Nicholson
Brian David Nicholson
NJNicholas R. Jones
Nicholas R. Jones
APAndrew Protheroe
Andrew Protheroe
JJJohnson Joseph
Johnson Joseph
NRNia Roberts
Nia Roberts
TFThomas R Fanshawe
Thomas R Fanshawe

1 October 2017 in European Journal of Cancer
Verified
Journal Article
Open access
HPH. De La Pena
H. De La Pena
ASAnand Sharma
Anand Sharma
CGC. Glicksman
C. Glicksman
JJJ. Joseph
J. Joseph
MSM. Subesinghe
M. Subesinghe
Marcia HallMarcia Hall
Marcia Hall
Following radical orchidectomy for testicular cancer, most patients undergo protocolled surveillance to detect tumour recurrences rather than receive adjuvant chemotherapy. Current United Kingdom national and most international guidelines recommend that patients require a chest x-ray (CXR) and serum tumour markers at each follow-up visit as well as regular CT scans; there is however, variation among cancer centres with follow-up protocols. Seminomas often do not cause tumour marker elevation; therefore, CT scans are the main diagnostic tool for detecting relapse. For non-seminomatous tumours, serum beta-HCG (HCG) and AFP levels are a very sensitive harbinger of relapse, but this only occurs in 50% of patients [1], and therefore, imaging remains as important. CXRs are meant to aid in the detection of lung recurrences and before the introduction of modern cross-sectional imaging in the early 1980s, CXRs would have been the only method of identifying lung metastasis. We examined the Thames Valley and Mount Vernon Cancer Centre databases to evaluate the role of CXRs in the 21st century for the follow-up of men with stage I testicular cancer between 2003 and 2015 to assess its value in diagnosing relapsed germ cell tumours. From a total of 1447 patients, we identified 159 relapses. All relapses were detected either by rising tumour markers or planned follow-up CT scans. Not a single relapse was identified on CXR. We conclude that with timely and appropriate modern cross-sectional imaging and tumour marker assays, the CXR no longer has any value in the routine surveillance of stage I testicular cancer and should be removed from follow-up guidelines and clinical practice. Omitting routine CXR from follow-up schedules will reduce anxiety as well as time that patients spend at hospitals and result in significant cost savings.

1 June 2018 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
RWRobert A. Watson
Robert A. Watson
RMRobert D. Morgan
Robert D. Morgan
JJJohnson Joseph
Johnson Joseph
SSShivan Sivakumar
Shivan Sivakumar
CVClare Verrill
Clare Verrill
APAndrew Protheroe
Andrew Protheroe